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Doxycycline is an antibacterial drug synthetically derived 
from oxytetracycline. It was approved by the American Food and 
Drug Administration (FDA) in 1967 [1] and is still used to treat 
a wide variety of bacterial infections and for the prophylaxis 
of malaria in short-term travellers (< 4 months). To reduce the 
development of drug-resistant bacteria and maintain effec-
tiveness, FDA recommends that doxycycline should be used 
only to treat or prevent infections that are proven or strongly 
suspected to be caused by susceptible bacteria [2]. In the ab-
sence of cultures, which is mostly the case in maritime-medical 
situations, local epidemiology and susceptibility patterns may 
contribute to the empiric selection of therapy.
Because doxycycline capsules are rather quickly and 
virtually completely absorbed after oral administration [2], 
they are popular in the maritime community where paren-
teral medication is often not readily available. Since bac-
teriostatic drugs may interfere with the bactericidal action 
of penicillin, it is advisable to avoid giving doxycycline in 
conjunction with penicillin [2]. 
The usual dosage and frequency of administration of 
doxycycline differs from that of the other tetracyclines. Dose 
and dosage form may influence the occurrence of adverse 
effects: Exceeding the recommended dosage may result in 
an increased incidence of side effects [2], and capsules con-
taining doxycycline hyclate in a powder formulation cause 
more gastrointestinal side effects like nausea, vomiting, and 
stomach or abdominal discomfort than capsules containing 
doxycycline hyclate as coated pellets [3]. 
Sequential labelling with fluorochromes is a standard 
technique for the investigation of bone remodelling in vivo. 
Tetracyclines are the only fluorochromes approved for hu-
man application, and — for oral administration — doxycycline 
is considered for its good bioavailability [4]. Because of their 
high affinity for calcium, tetracycline is incorporated at the 
site of active mineralisation of hydroxyapatite. A single oral 
dose of tetracycline can be traced by fluorescent microsco-
py in bone biopsies years after application [5, 6]. With an 
increasing percentage of female seafarers and a growing 
population of very young passengers on cruise ships, it is 
worth recalling that as with all tetracyclines, doxycycline is 
contraindicated in pregnancy through infancy and childhood 
up to 8 years of age, except for treatment of anthrax, due to 
the potential for disrupting bone and tooth development [7]. 
Even short courses may cause permanent discoloration of 
the teeth (yellow-grey-brown) and enamel hypoplasia [2]. 
Although sun block awareness protection has improved 
in general, patients should be told, particularly in the mar-
itime working environment and in cruise settings, to avoid 
excessive sunlight while receiving doxycycline because 
photosensitivity manifested by an exaggerated sunburn 
reaction is not uncommon. Therapy should be discontinued 
if phototoxicity (e.g., skin eruption, etc.) occurs [2].
And in such surroundings, where gastrointestinal con-
ditions are common, it is important to keep in mind that 
absorption of tetracyclines is impaired by antacids and 
laxatives containing aluminium, calcium, or magnesium, by 
bismuth subsalicylate, and by iron-containing preparations. 
Gastrointestinal absorption of doxycycline is reduced up to 
20% by food and/or milk, but this effect is not considered 
clinically important [2].
In this issue of “International Maritime Health”, Rot-
tenstreich, Rottenstreich and Shapira [8] present a naval 
crewmember who was diagnosed with oesophageal ulcers 
after taking doxycycline by mouth, thought to be caused by 
low pH and slow passage of the capsule through oesoph-
agus. In most previously reported cases horizontal patient 
position and too little concomitant fluid intake may have 
been contributing factors, whereas the present patient had 
been instructed to take the capsule with a glass of water 
and to sit up for at least 30 min afterward. Compliance 
regarding unwitnessed self-administration of medication is 
notoriously uncertain, yet the case is a good reminder that 
when prescribing doxycycline the patient should be carefully 
instructed on how to take the capsules. 
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The authors also speculate that intake of 330 mL beer 
several hours before taking the doxycycline capsule may 
have contributed to the oesophageal condition [8].
It is safe and — in a maritime setting for a variety of 
reasons — hardly wrong to advise against mixing alcohol and 
drugs. But there is no official FDA recommendation to stay 
away from alcohol during doxycycline therapy. Neither is it 
stated that the patient should remain in an upright position 
for a specified time after tablet intake, but it makes sense 
because in most cases of esophagitis and ulcers tetracycline 
had been taken in capsule and tablet form immediately 
before going to bed [2].
Administration of adequate amounts of fluid (“drink flu-
ids liberally”) along with capsule and tablet forms of drugs 
in the tetracycline class is recommended to wash down 
the drugs and reduce the risk of oesophageal irritation and 
ulceration. If gastric irritation occurs, it is recommended 
that doxycycline be given with food or milk, as this does not 
markedly influence the absorption [2].
Bed-ridden patients tend to sit up and take relatively 
high doses of doxycycline with a minimal sip of water be-
fore immediately reclining. And travellers to primitive tropic 
locations often receive their malaria prophylaxis weeks or 
months before starting and have to continue medication 
for 4 weeks after exposure. Prescription instructions are 
usually long forgotten and they often consider it easiest — 
and safest — to take their daily pill at bedtime with a little 
sip of a disinfecting (alcoholic) beverage just before slipping 
under the net. Ideally, detailed instructions on how to take 
the capsules should therefore be particularly stressed per-
son-to-person at prescription and be printed prominently, 
bold-faced and underlined on the medicine label. 
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